Integrated gene networks in breast cancer development
- 183 Downloads
Breast cancer is a complex and heterogenous disease. Classical molecular medical approaches cannot fully understand and comprehend its pathogenesis. In this review, the development of new biological markers for the early detection and creation of guided and specific therapy of breast cancer are discussed in light of the rapid advances in the “omics”. Results of cancer research in combination with large-scale methods that examine the expression status of genes and proteins have identified a large number of new biomarkers as well as confirmed the human growth hormone as an important player in the pathogenesis of this disease through its autocrine regulation where it influences the activation of Pax5 and HOXA1 gene networks.
KeywordsBreast cancer Proteomics Genomics hGH Pax5 HOXA1 Cancer profile
We greatly appreciate the financial help of the Foundation of Croatian Academy of Sciences and Arts. This manuscript was also supported by the project of Ministry of Science Education and Sports 098-0982464-2393.
This work has been approved by an ethical committee of Clinical hospital “Sisters of Mercy” and all subjects gave informed consent.
Conflict of interest
The authors declare that they have no competing interests.
- Børresen AL, Andersen TI, Eyfjörd JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S et al (1995) TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14(1):71–75CrossRefPubMedGoogle Scholar
- Fontana S, De Leo G, Sedic M, Kraljevic Pavelic S, Alessandro R (2006) Proteomics in antitumor research. DDT: technologies 3:441–449Google Scholar
- Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8(3):203–211CrossRefPubMedGoogle Scholar
- Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ, Hong SC, Choi SK, Ha WS, Kim JW, Lee CW, Lee JS, Park ST (2007) Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 120(11):2331–2338CrossRefPubMedGoogle Scholar
- Mohankumar KM, Xu XQ, Zhu T, Kannan N, Miller LD, Liu ET, Gluckman PD, Sukumar S, Emerald BS, Lobie PE (2007) HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells. Oncogene 26(27):3998–4008CrossRefPubMedGoogle Scholar
- Nimeus E, Malmstrom J, Johnsson A, Marko-Varga G, Ferno M (2006) Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy. J Pharm Biomed Anal 43(3):1089–1093Google Scholar
- Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM (2005) Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer 6:68CrossRefGoogle Scholar
- Saitoh S, Cunningham J, De Vries EM, McGovern RM, Schroeder JJ, Hartmann A, Blaszyk H, Wold LE, Schaid D, Sommer SS et al (1994) p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene 9(10):2869–2875PubMedGoogle Scholar